Platelet integrin αIIbβ3 plays a critical role in both hemostasis and thrombosis. Current αIIbβ3 antagonists are potent anti-thrombotic drugs, but also cause adverse outcomes, which limited their clinical use. Drug-induced serious bleeding, thrombocytopenia and paradoxical thrombosis have been linked to impaired clot retraction and to conformational changes in αIIbβ3 that promote binding of preformed antibodies, natural ligands or both to αIIbβ3. We have used structureguided design to generate the orthosteric inhibitor Hr10 that acts as a pure αIIbβ3 antagonist, i.e. it does not induce the conformational changes in αIIbβ3. Hr10 is as effective as the partial agonist drug eptifibatide in blocking platelet aggregation and arteriolar thrombosis in mice. In contrast to eptifibatide, however, Hr10 preserved thrombin-induced clot retraction, suggesting that it may not perturb hemostasis. Our structure-based approach can find general utility in designing pure orthosteric inhibitors for other integrins, in providing vital tools for dissecting structureactivity relationships in αIIbβ3, and potentially in offering safer alternatives for human therapy.
Platelet activation and accumulation at the site of blood vessel injury are the initial steps in hemostasis. Activated platelets adhere to the disrupted surface and aggregate upon binding of αIIbβ3 to soluble fibrinogen 1, 2 . Fibrin generated by thrombin at or near the platelet surface also binds αIIbβ3, driving clot retraction 3 , thereby consolidating the integrity of the hemostatic plug, restoring blood flow and promoting wound closure 4 . Excessive platelet activation after rupture of atherosclerotic plaques, for example, may lead to formation of occlusive thrombi, which are responsible for acute myocardial infarction and stroke, leading causes of death in developed countries 5 . It may also contribute to fibril formation in cerebral vessels of Alzheimer's disease patients 6 . The three parenteral αIIbβ3 antagonists (eptifibatide, tirofiban and abciximab) have demonstrated efficacy in reducing death and ischemic complications in victims of heart attacks 7 . However, their clinical use in acute coronary syndrome has been associated with significant risk of bleeding. And orally active anti-αIIbβ3 agents administered to patients at risk of acute coronary syndromes and other cardiovascular diseases were abandoned because of unexpected increased risk of patient death, linked to paradoxical thrombosis [8] [9] [10] . These adverse outcomes have limited use of direct αIIbβ3 antagonists to high-risk cardiac patients undergoing primary percutaneous coronary interventions 11, 12 , and contributed to the development of alternative anti-platelet drugs such as inhibitors of the adenosine diphosphate (ADP) receptor P 2 Y 12 and the thrombin receptor PAR1, both activators of αIIbβ3, but use of these drugs still causes serious bleeding 13, 14 .
Biochemical and clinical studies showed that the three anti-αIIbβ3 drugs are partial agonists, triggering conformational changes in αIIbβ3 that paradoxically enhance its binding to physiologic ligand thus promoting thrombosis 15, 16 , and also expose neoepitopes in αIIbβ3 for natural antibodies, causing immune thrombocytopenia 17 . These drugs further increase bleeding risk by impairing clot retraction [18] [19] [20] , which may require cessation of therapy, putting heart attack victims at high risk of re-thrombosis. Concluding that αIIbβ3 antagonism and partial agonism are inseparable, pharmaceutical companies veered away from further drug development directly targeting αIIbβ3.
The X-ray structures of unoccupied and ligand-bound αVβ3 ectodomain 21, 22 elucidated the structural basis of ligand binding and the associated conformational changes in the integrin. These studies showed that ligand binding triggers tertiary changes in the ligandbinding βA domain of the β3 subunit, comprising the inward movement of the α1 helix (reported by β3-Tyr 122 ) towards the metal ion at the metal ion-dependent adhesion site (MIDAS) and reshaping the F-α7 loop and the α7 helix. These changes trigger quaternary shape shifts including a swing-out movement of the hybrid domain underneath βA 23 , leading to integrin genu-extension from its default genu-bent conformation (reviewed in 24 ). These shape shifts expose neoepitopes in integrin αIIbβ3 for both natural antibodies and conformation-sensitive mouse monoclonal antibodies (mAbs), and promote physiologic ligand binding in the absence of an activating agent 16, 25 . More recently, we showed that the global shape-shifts in αVβ3 are prevented by binding of the first "pure" αVβ3 antagonist, hFN10, a mutant form of the 10 th type III domain of fibronectin (FN10) 26 . This is achieved by formation of a π-π interaction between the β3-Tyr 122 of the inactive integrin with the indole derivative, tryptophan, that immediately follows the RGD motif of hFN10 26 . However, the general applicability of this approach for generating pure antagonists for other integrins has not been explored.
In this report, we use the crystal structure of αVβ3/hFN10 complex (4mmz.pdb) to generate the peptide Hr10. Hr10 binds αIIbβ3 and maintains pure orthosteric integrin inhibition. Hr10 effectively blocks platelet aggregation induced not only by ADP but also by collagen or thrombin receptor activating peptide (TRAP). Hr10 is as effective as the partial agonist eptifibatide (Integrlin®) in inhibiting thrombosis in a mouse model that is used as predictor of clinical efficacy of platelet agents 27 . Unexpectedly, and in contrast to eptifibatide, Hr10 did not block clot retraction at effective anti-thrombotic concentrations. These data show the feasibility of using our structure-based approach to develop pure antagonists of other integrins, and suggest that such agents could offer safer and effective therapeutic alternatives to current anti-integrin drugs.
Results

Development of
Hr10. The inability of hFN10 to bind αIIbβ3 28 was investigated by superimposing the crystal structure of eptifibatide-bound αIIbβ3 (2vdn.pdb) onto that of hFN10-bound αVβ3 26 (Figure 1 ). This analysis revealed a potential clash involving residues Ser 1500 -Lys of the C-terminal F-G loop of hFN10 and Val 156 -Glu in the longer helix-containing D2-A3 loop of the αIIb propeller domain. In addition, the shorter ligand Arg 1493 of hFN10 cannot make the critical bidentate salt bridge with αIIb-Asp 224 in the deeper pocket of the αIIb propeller ( Figure 1 ). We therefore substituted Ser 1500 -Lys in hFN10 with Gly, and replaced the ligand Arg 1493 with the longer L-homoarginine (Har) as described 29 , changes that we predicted would not adversely affect FN10 folding or the apparently key π-π interaction between β3-Tyr 122 and Trp 1496 , and would make Hr10 a novel ligand for αIIbβ3. The site-specific replacement of Arg 1493 with Har 1493 in the resulting ligand-mimetic peptide Hr10 was confirmed by mass spectroscopy ( Supplementary Fig. 1 ).
Hr10 binds and blocks soluble fibrinogen binding to αIIbβ3. We first assessed if the introduced sequence changes affected binding of Hr10 to cellular β3 integrins. This was determined by quantifying binding of Hr10 and hFN10 to the erythroleukemic cell line K562 stably expressing recombinant αIIbβ3 (αIIbβ3-K562) or αVβ3 (αVβ3-K562) in buffer containing 1mM each of Ca 2+ and Mg 2+ . Hr10 but not hFN10 bound αIIbβ3-K562 ( Fig.2a ) but maintained its capacity to bind αVβ3-K562 vs. hFN10, which only bound αVβ3-K562 ( Fig.2a ). We next compared the effects of Hr10, hFN10 and eptifibatide on soluble fibrinogen (FB) binding to αIIbβ3 preactivated by binding of mAb PT-25-2 30 , (αIIbβ3 preactivation is required for binding of physiologic ligand). Hr10 inhibited binding of Alexa647-labeled FB to preactivated αIIbβ3 in a dose dependent manner ( Figure 2b) , and was ~2-fold more effective in this function when compared to eptifibatide (IC 50 for Hr10 calculated from the curves fit to the points yielded 30.3±4.8 nM [mean ± S.E., n=3] vs. 73.2 ± 7.0 nM for eptifibatide (p=1.79x10 -5 )). hFN10 bound minimally to activated αIIbβ3-K562, with an order of magnitude greater IC 50 of 474.0±73.4 nM ( Figure 2b ).
Crystal structure of αVβ3/Hr10 complex. To elucidate the structural basis of Hr10 binding to both β3 integrins, we soaked Hr10 into preformed αVβ3 ectodomain crystals (crystal packing of the αIIbβ3 ectodomain does not allow access of large peptides to the integrin binding site). A diffraction dataset to 3.1 Å was obtained for the αVβ3/Hr10 complex ( Table 1 ). Clear densities for Hr10 and the metal ions at LIMBS, MIDAS and ADMIDAS were seen at the RGD-binding pocket (Figure 2c ). The ligand Har 1496 (replacing Arg) is lined with αV-Tyr 178 and αV-Asp 218 , and forms a bidentate salt bridge with αV-Asp 218 , and a cation-π interaction with αV-Tyr 178 , but does not contact αV-Thr 212 (which replaces αIIb-Asp 224 ). The ligand Asp 1495 directly coordinates the metal ion at MIDAS. Significantly, Trp 1496 of Hr10 is able to make a π-π interaction with βA-Tyr 122 , stabilized by an S-π interaction with βA-Met 180 (Figure 2c ) and by a hydrogen bond between the carbonyl of Trp 1496 and Nε of βA-Arg 214 , contacts also seen in the αVβ3/hFN10 structure 26 . Binding of Hr10 freezes the βA domain in the inactive conformation by preventing the activating inward movement of the α1 helix (reported by β3-Tyr 122 ) towards MIDAS, and the large change in the F-α7 loop 26 . Superposition of the βA domains from the αVβ3/Hr10 and αIIbβ3/eptifibatide structures show that the introduced Ser 1500 -Lys/Gly substitution removes the predicted clash with the helical residues in the D2-A3 loop of the αIIb propeller ( Figure 2d , compare with Figure 1 ). Nε, Nh1 and Nh2 amino groups of the ligand Har 1493 superpose well on those of Har 2 in eptifibatide, and could likewise form the bidentate salt bridge with αIIb-Asp 224 as in the αIIbβ3/eptifibatide structure, accounting for the ability of Hr10 to also bind αIIbβ3 and block its binding to soluble FB.
Binding of Hr10 does not induce the activating conformational changes in αIIbβ3 and prevents ADP-induced αIIbβ3 activation. Binding of eptifibatide to human platelets at the clinically-effective plasma concentration of 1.5 µM in the absence or presence of 5 µM ADP induced global conformational changes in αIIbβ3, as reported by binding of the activation-sensitive and extension-sensitive mAbs AP5 31 and LIBS-1 32 , respectively (Figure 3a, b) . In contrast, Hr10 at 1.5 µM did not induce binding of AP5 or LIBS-1 to platelet αIIbβ3 and also suppressed AP5 and LIBS-1 binding to ADP-preactivated platelets (Figure 3a, b) . These data suggest that Hr10 can reverse the global conformational changes in platelet αIIbβ3 triggered by ADP.
Effects of Hr10 on platelet aggregation and secretion. Next, we compared the effects of Hr10 and eptifibatide on human platelet aggregation in whole blood using standard concentrations of three agonists: collagen (1µg/ml), ADP (20 µM), and TRAP (10 µM). Hr10 was as effective as eptifibatide in blocking collagen-induced platelet aggregation, but was slightly (~2-fold) less effective in blocking aggregation induced by ADP or TRAP (Figure 4a-d ).
Agonist-induced platelet activation is accompanied by release of the contents of αgranules, dense (δ-) granules and lysosomes, through fusion of these organelles with the plasma membrane. Both Hr10 and eptifibatide at the saturating 1.5 µM concentration (which inhibited platelet aggregation completely) blocked early ATP secretion from dense granules in whole blood following platelet activation with 20 µM ADP ( Figure 4e ). Hr10 inhibited ATP secretion by 71 ± 14 %, which is comparable to that seen with eptifibatide (60 ± 20 %)( Figure 4e ). Secretion from human platelet α-granules (reported by CD62 expression) and lysosomal degranulation (reported by CD63 expression) in presence of Hr10 or eptifibatide were comparable following activation with 20 µM ADP ( Figure 4f ). Due to platelet aggregation, it was not possible to measure the amount of αgranule secretion and lysosomal degranulation following ADP activation in the absence of inhibitors. Abciximab and tirofiban are also reported to exert no 33, 34 or only partial 35 inhibition of platelet α-granule secretion Hr10 does not inhibit thrombin-induced clot retraction. Thrombin-induced clot retraction has been shown to positively correlate with the increased bleeding risk associated with use of eptifibatide and tirofiban [18] [19] [20] . We quantified the effect of Hr10 vs. eptifibatide, each at the saturating anti-aggregatory concentration of 1.5 µM, on thrombin-induced clot retraction in fresh human platelet-rich plasma (PRP) 36 . The kinetics of clot retraction were determined from quantification of serial images of the reaction acquired every 15 minutes for the 2-hour duration of the assay. As shown in Figure 5a -g, the kinetics of clot retraction in the absence or presence of Hr10 were nearly identical. In contrast, eptifibatide significantly inhibited clot retraction, as previously shown 20, 37 . It has been proposed that anti-αIIbβ3 drugs that block both platelet aggregation and clot retraction bind inactive and active αIIbβ3 with similar high affinity 3 . As shown in Figure 5h , however, dose-response curves showed that affinity of Hr10 to inactive αIIbβ3 (IC 50 =58.8+24.1 nM, 9 determinations of 5 experiments) is not significantly different from that to PT-25-activated αIIbβ3 (IC 50 35 .2+5.7 nM, n=3 experiments; p=0.054), and is comparable to the affinity of eptifibatide to resting platelets (k D =120 nM) 38 .
Hr10 blocks microvascular thrombosis in vivo.
To evaluate the effects of Hr10 vs. eptifibatide on nascent thrombus formation under flow, we used the thrombin-mediated arteriolar injury model in mice, known to predict the clinical efficacy of anti-platelet agents 27 . We used NSG (NOD-scid-IL-2Rγ null ) mice 39 that were also homozygous for human von Willebrand factor R1326H (VWF RH/RH ), which switches preferential binding from mouse to human glycoprotein (GP) Ib/IX, thus promoting incorporation of human over mice platelets into thrombi 40 . Use of these humanized mice is necessary as Hr10, like eptifibatide 27 , binds poorly to mouse αIIbβ3 (not shown). Hr10 and eptifibatide in equimolar concentrations were equally effective in preventing nascent occlusive thrombus formation at sites of laser-induced arteriolar injury ( Figure 6 ).
Discussion
Hr10 is the first high affinity RGD-based inhibitor to function as a pure antagonist of αIIbβ3. A previous study showed that a non-RGD small molecule, RUC-2, also binds αIIbβ3 without activating this receptor; it works by occupying the Arg pocket in αIIb and destabilizing the Mg 2+ at MIDAS, effects reversed, however, at high Mg 2+ concentrations 41 . Hr10 makes multiple contacts with the ligand-binding βA domain, accounting for its stable high affinity binding to the integrin. The ability to generate a pure antagonist for another integrin, guided by the crystal structure of the αVβ3/hFN10 complex 26 , suggests that existing RGD-like partial agonists like eptifibatide or tirofiban could be similarly engineered into new pure orthosteric antagonists.
Hr10 shared with eptifibatide the ability to effectively block soluble FB binding to activated αIIbβ3 as well as agonist-induced platelet aggregation at nearly equivalent IC 50 s (varying only by two fold in either direction). At the clinically effective eptifibatide concentration of 1.5 µM, Hr10 was as effective in blocking ATP secretion in vitro and arteriolar thrombosis in vivo. One major difference from eptifibatide, however, is the ability of Hr10 to prevent the activating shape-shifts in the integrin that initiate proadhesive outside-in signaling 42 . This was evidenced by inhibition of binding of the activation-sensitive mAb AP5 and the extension-sensitive mAb LIBS-1 to αIIbβ3. Hr10 not only fails to initiate conformational changes on its own but also prevented the conformational changes in αIIbβ3 induced by inside-out signaling generated through binding of ADP to the P 2 Y 12 platelet receptor. The crystal structure of Hr10 in complex with αVβ3 revealed the structural basis of this pure antagonism: Hr10 froze βA in the inactive conformation, enabled by the central π-π contact of Hr10-Trp 1496 with β3-Tyr 122 . The dual specificity of Hr10 to both β3 integrins is also explained by the ability of Hr10's homoarginine to make a salt bridge with αV-Asp 218 , and expectedly with αIIb-Asp 224 . β3-Tyr 122 is replaced with Phe 122 in mouse β3, and the stabilizing salt bridge β3-Arg 214 makes with β3-Asp 179 is replaced with a H-bond with β3-Asn 179 in mouse, both substitutions likely contributing to the poor binding of Hr10 to mouse αIIbβ3.
Hr10 is also distinguished from eptifibatide by its ability to preserve thrombin-induced clot retraction at equimolar concentrations that fully inhibit agonist-induced platelet aggregation. Clot retraction occurs in response to αIIbβ3-fibrin mediated actomyosin interaction 4, 19 , and is thought to secure hemostasis in vivo, as evidenced by increased bleeding in mice with impaired clot retraction 43 , as well as in recipients of all three current clot-retraction inhibitory anti-αIIbβ3 drugs 18, 20, 37 . The underlying mechanism(s) for this unexpected difference between Hr10 and eptifibatide is not entirely clear. It has recently been shown that polymeric fibrin binds αIIbβ3 with higher affinity when compared with monomeric FB 44 , suggesting that the high affinity of the three current anti-αIIbβ3 drugs is necessary to block fibrin-αIIbβ3 interaction and hence clot retraction. However, Hr10 and eptifibatide have nearly equivalent IC 50 s in blocking soluble FB binding to activated αIIbβ3 and in inhibiting agonist-induced platelet aggregation. Others have found that drug candidates that block both platelet aggregation and clot retraction bind with similar high affinity to active and inactive αIIbβ3, whereas those that block only aggregation have an affinity that is 2-3 logs lower to inactive vs. active αIIbβ3 3, 45 .
Our data, however, shows no significant differences in high affinity binding of Hr10 to inactive and active αIIbβ3 (Fig. 5h) . A recent study showed that fibrin binds αIIbβ3 even when its RGD-motifs (C-terminal γA chain motif essential for FB binding, and the two αA chain RGD motifs) are deleted 44 , indicating the presence of additional fibrin binding sites in αIIbβ3 that mediate fibrin-dependent clot contraction. These were recently localized in the αIIb propeller domain, i.e. are distinct from MIDAS 46 . Previous studies have also shown that non-activated platelets can adhere to surface-immobilized fibrin(ogen) 47, 48 . Thus one interpretation of the present data is that occupancy of non-RGD binding sites in Hr10-bound αIIbβ3 by polymeric insoluble fibrin still allows the αIIbβ3-dependent intracellular tyrosine de-phosphorylation required for clot retraction, a process otherwise blocked by eptifibatide-bound αIIbβ3 37 . The availability of pure orthosteric antagonists of αIIbβ3 should provide a vital tool to dissect the contribution of integrin conformation to platelet function.
The dual specificity of Hr10 to both β3 integrins is shared with the drug abciximab 49 . Hr10, likewise, may be able to simultaneously prevent αVβ3-mediated thrombin generation, smooth muscle cell migration and proliferation, properties thought to contribute to the long-term clinical benefits of abciximab in acute coronary syndromes 50 51 . In addition, dual specificity to both β3 integrins has previously shown a wide range of anticancer effects (reviewed in 52 ). Dual β3 antagonism with abciximab, for example, was effective at blocking tumor growth and angiogenesis through targeting the interaction of tumor cells with platelets and endothelial cells, in addition to direct effects on the tumor tissue [53] [54] [55] [56] . Hr10, a minor variant of a natural ligand that also does not prevent clot retraction, offers an attractive clinical candidate over abciximab, whose use has been associated with both immunogenicity and serious bleeding.
A commonly held view in the field is that effective inhibition of thrombosis by targeting αIIbβ3 cannot be achieved without compromising hemostasis, thus causing significant bleeding and increased morbidity and mortality. The data presented in this communication show that the pure ligand-mimetic antagonist Hr10, at concentrations that completely inhibit agonist-induced platelet aggregation in vitro and thrombosis in vivo, not only blocks integrin shape-shifting that can trigger immune thrombocytopenia or paradoxical thrombosis, but also preserves thrombin-induced clot retraction. These findings suggest that pure orthosteric inhibition of αIIbβ3 may offer a safer antithrombotic strategy with minimal perturbation of hemostasis.
Methods
Reagents and antibodies.
Restriction and modification enzymes were obtained from New England Biolabs Inc. (Beverly, MA). Cell culture reagents were purchased from Invitrogen Corp (San Diego, CA) or Fisher Scientific (Hampton, NH). Mouse mAbs AP5 and LIBS-1 were kindly provided, respectively, by T.J. Kunicki (Blood Centre, Madison, WI) 31 and Dr. M. Ginsberg (University of California, San Diego) 32 . The Fab fragment of AP5 was prepared by papain digestion followed by anion exchange and size-exclusion chromatography. mAb PT-25-2 was the kind gift of Dr. Makoto Handa (Keio University, Tokyo, Japan) 30 . Hybridoma producing the β3 conformation-insensitive mAb AP3 was bought from ATCC and the antibody purified by Protein-A affinity chromatography. Alexa Fluor 488-conjugated mAbs directed against human CD62 and CD63 were bought from Santa Cruz Biotechnology, Dallas, TX. Alexa Fluor647-conjugated anti human CD42b mAb was purchased from R&D Systems, Minneapolis, MN. APC-labeled goat anti-mouse Fc-specific antibody was from Jackson ImmunoResearch (West Grove, PA). Alexa Fluor 647-conjugated Penta-His mAb was purchased from Qiagen, Germantown, MD. The plasmid pCDF5-Har, containing two copies of a UAG recognizing tRNA and the tRNA synthase (Har-Rs) for charging UAG tRNAs with Har, and the E. coli strain B-95ΔA containing a deletion of release factor 1 (prfA) and 95 synonymous TAG stop codon mutations, were kindly provided Dr. Kensaku Sakamoto (RIKEN, Yokohama, Japan) 29 . L-Har and TRAP-6 were purchased from Bachem. ADP, collagen, ATP, Chrono-luminescence reagent and human thrombin were purchased from Chrono-log (Havertown, PA).
Plasmids, mutagenesis, protein expression, purification and mass spectrometry.
Human αVβ3 ectodomain was expressed in insect cells and purified as described 26 . hFN10 was expressed in BL21-DE3 bacteria and purified by affinity chromatography on nickel columns followed by gel filtration as described 26 . hFN10 containing a TAG stop codon at position 1493 was generated by PCR-based mutagenesis with the Quick-change kit (Agilent Technologies), cloned into bacterial expression plasmid pET11a and verified by DNA sequencing. Hr10 was expressed in B-95ΔA containing plasmids pCDF5-Har and pET-11a/hFN10-TAG in LB media supplemented with 5 mM L-Har, 50 µg/ml kanamycin (pCDF5-Har) and 100 µg/ml ampicillin (pET-11a). Cultures at ~0.5 A (600 nm) were induced with 0.3 mM IPTG and grown for 8 hours at room temperature. Hr10 was purified as for hFN10. Mass Spectrometry of purified Hr10 was performed at the Taplin Biological Mass Spectrometry Core Facility at Harvard Medical School (Boston MA) as described in 57 .
Cell lines, cell culture and transfection. Human αVβ3-K562 cells have been previously described 26 . K562 cells stably expressing αIIβ3 (αIIβ3-K562) were kindly provided by Jennifer Cochran (Stanford University, CA) 58 . K562 cells were maintained in Iscove's modified Dulbecco's medium plus G418 (0.5-1.0 mg/ml), supplemented with 10% fetal calf serum, 2mM L-glutamine, penicillin and streptomycin.
Ligand binding and flow cytometry. For ligand binding assays, αIIβ3-K562 or αVβ3-K562 cells (1×10 6 ) were suspended in 100µl of WB (20 mM Hepes, 150 mM NaCl, pH 7.4, containing 0.1% [w/v] bovine serum albumin and 1mM each of MgCl 2 and CalCl 2 ) and incubated first with Hr10 or hFN10 (each at 3-10 µg/ml) for 30 min at room temperature (RT). After washing, cells were incubated for 30 additional minutes at 4°C with Alexa Fluor 647 conjugated Penta-His mAb. Integrin expression was independently analyzed for each condition by incubating cells with the Alexa647-conjugated AP3 (10 µg/ml) for 30 min on ice. Cells were washed, re-suspended, fixed in 2% paraformaldehyde and analyzed using FACSCalibur or BD-LSRII flow cytometers (BD Biosciences). Ligand binding was expressed as mean fluorescence intensity (MFI), as determined using FlowJo software. Mean and SD from independent experiments were calculated, and compared using Student's t test.
For ligand binding competition studies, 100µl of PT-25-activated αIIbβ3-K562 (1×10 6 ) were incubated for 30 minutes at RT with serially diluted concentrations of Hr10, hFN10 or eptifibatide in the presence of 0.5 µM Alexa647-conjugated FB. Cells were washed, fixed in 2% paraformaldehyde and analyzed by flow cytometry. Ligand binding was expressed as IC 50 of cells in the absence of competitor ligands. Mean and SD from three independent experiments were calculated, and compared using Student's t test.
Platelet aggregation and ATP secretion. Platelet aggregation and ATP secretion in whole blood were performed in a Chrono-Log model 700 two-channel lumi-aggregation system following the manufacturer's instructions. Blood was drawn from healthy volunteers directly into 3.2% sodium citrate and used within 3 hours. For impedance aggregation measurements, 0.5 ml of blood was mixed with 0.5 ml physiologic saline supplemented with inhibitors and incubated at 37 o C for 5 minutes without stirring. Measurements were performed with stirring at 1,200 rpm at 37 o C. Values for each data point represent impedance measurements following application of agonist integrated over 5 minutes. Data points for an individual dose curve were serially collected from a single draw and analyzed with SigmaPlot (Systat Software, San Jose, CA) using a least-square fit to a logistic curve and the IC 50 value determined from the fitted parameter. ATP secretion proceeded similarly except that 0.45 ml of whole blood were added to 0.45 ml of saline supplemented with various concentrations of Hr10 or eptifibatide to produce the desired concentration at 1.0 ml. Following incubation for 5 minutes at 37 o C, 100 µl of Chrono-lume reagent was added and aggregation initiated. The luminescence signal was quantified with a non-aggregated sample supplemented with an ATP standard.
Binding of mAbs. αVβ3-K562 cells or transiently transfected HEK293T (0.5×10 6 in 100 µl WB) were incubated in the absence or presence of unlabeled Hr10 or eptifibatide, each at 1.5µM, for 20 min at RT. Alexa647-labeled AP5 Fab or unlabeled anti-LIBS-1 (each to 10 µg/ml) were added, and cells incubated for an additional 30 min before washing. Alexa647-labeled AP3 was used for normalization of integrin expression. APC-labeled goat anti-mouse Fc-specific antibody was added to anti-LIBS-1-bound cells for an additional 30 min at 4°C, cells washed and processed for flow cytometry. Binding of anti-CD62 and anti-CD63 mAbs to platelets was performed by incubating (20 min, RT) 100 µl of ligand-pretreated 3.2% sodium citrate whole blood with either Alexa488labeled mAb (at 10 µg/ml) in the presence of 10 µg/ml Alexa647-labeled anti-CD42b. Cells were fixed in 2% paraformaldehyde and CD62 and CD63 expression was analyzed by flow cytometry in the CD42b positive population.
Crystallography, structure determination and refinement. Human αVβ3 ectodomain was purified and crystallized by the hanging drop method as previously described 21 . Hr10 was soaked for 3 weeks into the preformed αVβ3 crystals at 1.5 mM in the crystallization well solution containing 1 mM Mn 2+ . Crystals were harvested in 12% PEG 3500 (polyethylene glycol, molecular weight 3500), in 100 mM sodium acetate, pH 4.5, 800 mM NaCl plus 2 mM Mn 2+ and FN10 (at 1.5 mM), cryoprotected by addition of glycerol in 2% increments up to 24% final concentration, and then flash-frozen in liquid nitrogen. Diffraction data was collected at ID-19 of APS, indexed, integrated, scaled by HKL2000 59 , and solved by molecular replacement using 3IJE as the search model in PHASER 60 . The structure was refined with Phenix 61 using translation-liberation-screw, automatic optimization of X-ray and stereochemistry, and Ramachandran restriction in the final cycle. Data collection and refinement statistics are shown in Table 1 . The coordinates and structure factors of αVβ3/Hr10 have been deposited in the Protein Data Bank under accession code 6NAJ. Structural illustrations were prepared with Chimera 62 .
Cremaster laser injury animal studies. Human blood was collected in 0.129 M sodium citrate (10:1 vol/vol). Platelet-rich plasma (PRP) was separated after centrifugation (200g, 10 minutes) at room temperature (RT). The platelets were then isolated from PRP, and prostaglandin E1 (Sigma-Aldrich) added to a final concentration of 1 µM. Platelets were then pelleted by centrifugation (800g, 10 minutes) at RT. The pellet was washed in calcium-free Tyrode's buffer (134 mM NaCl, 3 mM KCl, 0.3 mM NaH 2 PO 4 , 2 mM MgCl 2 , 5 mM HEPES, 5 mM glucose, 0.1% NaHCO 3 , and 1 mM EGTA, pH 6.5), and resuspended in CATCH buffer (PBS and 1.5% bovine serum albumin, 1 mM adenosine, 2 mM theophylline, 0.38% sodium citrate, all from Sigma-Aldrich). Platelet counts were determined using a HemaVet counter (Drew Scientific). Intravital microscopy was performed as previously described 63 64 . vWF RH/RH NSG male mice were studied after being anesthetized using sodium pentobarbital (80 mg/kg) injected intraperitoneally. Mice were maintained under anesthesia with the same anesthetic delivered via a catheterized jugular vein at 5 mg/ml throughout the experiment. The cremaster muscle was surgically exteriorized and continuously superfused with a physiological buffer (PBS containing 0.9 mM CaCl 2 and 0.49 mM MgCl 2 ) maintained at 37°C throughout the entire experiment and equilibrated with a mixture of 95% N2 and 5% CO2. Human platelets, 400 million per mouse, were labeled with mouse anti-human CD41 F(ab′)2 (BD Biosciences) conjugated to Alexa Fluor-488 and infused into the jugular vein, followed by Alexa Fluor-647 rat anti-mouse CD41 F(ab′)2 (Thermo Fisher) to detect endogenous mouse platelets 65 . Vascular injury was induced with an SRS NL100 pulsed nitrogen dye laser (440 nm) focused on the vessel wall through the microscope objective. Each injury was followed for three minutes. Eptifibatide was used at 5µg/mouse (equivalent to the clinically effective dose of ~1.5 µM 66 ) and Hr10 at the equimolar concentration (60 µg/mouse). Drugs were infused 5 minutes prior to injury via the jugular vein. Pre and post drug measurements were made in the same animal. Wide-field images of thrombi were recorded using a Hamamatsu ORCA Flash 4.0 V3 CMOS camera (Hamamatsu, Japan) coupled to a Excelitas X-Cite XLED light source. The microscope, cameras, and light sources were all controlled using Slidebook 6.0 software (Intelligent Imaging Innovations). Intensity of the fluorescent signal was used to measure incorporated platelets 64 . Eight injuries were made in each of four mice in each group.
Clot retraction assay. 750 µl of Tyrode's buffer supplemented with inhibitor was mixed in a glass culture tube with 200 µl of PRP and 5 µl red blood cells. Clotting was initiated by addition of 50 µl thrombin at 10 units/ml in saline and a sealed Pasteur pipette secured in the tube center. Digital photographs of the experiment were taken at 15-minute intervals over 2 hours. Images were analyzed with ImageJ software to determine the area occupied by the clot and plasma. Plots of the relative areas and linear regressions were performed with SigmaPlot (Systat Software, San Jose, CA).
Statistical calculations.
Dose response experiments for whole blood aggregation and binding in K562 cells were conducted at least three times. Curve-fitting and statistical calculations were performed in SigmaPlot. The data points from each replicate were scaled to one another by an initial fit to a sigmoidal function to determine the minimum and maximum values. Data scaled to a maximum of 1 and a minimum of 0 were combined and fit to a sigmoidal curve to determine the IC 50 value. The standard error for the IC 50 estimate was calculated using the reduced χ 2 method. P-values comparing IC 50 s from different inhibitors were determined using the global fit function in SigmaPlot. The two data sets were fit with all parameters separate and again where the IC 50 value is shared between the data sets. Fisher's F statistic was calculated from the residual sum of squares and degrees of freedom for the unshared (SS un , DF un ) and shared (SS sh , Df sh ) with the equation F=((SS sh -SS un )/(DF sh -DF un ))/(SS un /DF un ) and the P-value obtained from the F distribution. Linear regression fits to data from clot retraction experiments proceeded similarly. The Holm-Sidak test following one-way ANOVA (alpha=5.0%) was used to assess if the differences in human platelet accumulation in thrombi between Hr10 and eptifibatide-treated mice were significant. Each time point was analyzed individually, without assuming a consistent standard deviation. The MIDAS ion is ligated by the aspartate residue from each ligand. Residues (single letter code) specific to each structure are shown in the respective color, with residues or loops common in both indicated in black. Oxygen, nitrogen, and sulfur atoms are in red, blue and yellow, respectively. The inward movement (red arrow) of the α1 helix and ADMIDAS ion in αIIbβ3, driven by binding of the partial agonist eptifibatide, is absent in hFN10-bound αVβ3, the result of a π-π interaction between ligand W 1496 and β3-Y 122 . β3-R 214 and β3-M 180 contribute to the stability of ligand W 1496 . The homoarginine from eptifibatide forms a bidentate salt bridge with αIIb-D 224 (replaced by T 212 in αV), whereas R 1493 of hFN10 contacts αV-D 218 (replaced by F 231 in αIIb). A clash between the c-terminal F-G loop of hFN10 and the longer D2-A3 loop of the αIIb propeller, replacement of D 218 in αV with F 231 in αIIb and the shorter side chain of R 1493 (vs. homoarginine in eptifibatide) are predicted to account for the poor binding of hFN10 to αIIbβ3. Side-chains are shown as sticks in the respective colors. Oxygen, nitrogen, and sulfur atoms are in red, blue and yellow, respectively. The Mn 2+ ions at the LIMBS, MIDAS and ADMIDAS are in grey, cyan, and magenta spheres, respectively. Water molecules are not shown. The Hr10 ligand W 1496 forms a π-π interaction with β3-Y 122 , and Har 1493 forms a bidentate salt bridge with αV-D 218 . The view is identical to that in Fig. 1. d ) Ribbon diagrams of the crystal structures of αVβ3/Hr10 (light green) and αIIbβ3/eptifibatide (light purple) superposed on the βA domain of each. The view is identical to that in (c) and in Fig.1 . Nε, Nh1 and Nh2 amino groups of Har 1493 superpose nicely onto those of Har 2 of eptifibatide (dark gray). Domain, side chain and metal ion colors are as in Fig.1 and (c) . Note the removal of the predicted clash of Hr10 with D2-A3 loop of αIIb and predicted formation of a bidentate salt bridge between ligand Har 1493 and αIIb-D 224 . 
